97183 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
Anti-CLL-1 antibodies and immunoconjugates
#602Hyperglycosylated binding polypeptides
#603SELF-BUFFERING PROTEIN FORMULATIONS
#604TEM-1 diagnostic antibodies
#605Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses
#606COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD22 ANTIBODY-DRUG CONJUGATE
#607Antibodies specific for LOX1 and use in treatment of cardiovascular disorders
#608Chimeric receptors and methods of use thereof
#609Antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes
#610Anti-TEM1 antibodies and uses thereof
#611Humanized anti-CD22 antibody
#612Site-specific antibody-drug conjugation through glycoengineering
#613PRO-DRUG FORM (P2PDOX) OF THE HIGHLY POTENT 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED THERAPY OF CANCER
#614Subcutaneous administration of anti-CD74 antibody for systemic lupus erythematosus
#615Methods of treating cardiovascular disorders with lectin-like oxidized LDL receptor 1 antibodies
#616CD94/NKG2A AND/OR CD94/NKG2B ANTIBODY, VACCINE COMBINATIONS
#617T-cell redirecting bispecific antibodies for treatment of disease
#618Methods for treating thrombosis using chimeric and humanized anti-histone antibodies
#619Pseudomonas exotoxin A with less immunogenic B cell epitopes
#620Depletion of plasmacytoid dendritic cells
#621Depletion of plasmacytoid dendritic cells
#622Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#623Compositions and methods for targeting of the surfactant protein A receptor
#624Isoquinolidinobenzodiazepines
#625GALECTIN IMMUNOTHERAPY
#626Methods of treating cardiovascular disorders with lectin-like oxidized LDL receptor 1 antibodies
#627BIOLOGICAL PRODUCTS
#628Method for purifying active polypeptides or immunoconjugates
#629ANTI-SIGLEC-15 ANTIBODIES FOR USE IN TREATMENT OF OSTEOGENESIS IMPERFECTA
#630Genetically modified non-human mammals and cells
#631Humanized anti-IgE antibodies that crosslink CD23 on B lymphocytes but do not sensitize mast cells
#632Methods and compositions for treating systemic mastocytosis
#633Methods and compositions for treating autoimmune and inflammatory conditions
#634METHODS AND COMPOSITIONS FOR TREATING ALLERGY AND INFLAMMATORY DISEASES
#635Dock-and-Lock (DNL) Complexes for Therapeutic and Diagnostic Use
#636Methods of treating cardiovascular disease with an ASGR inhibitor
#637Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells
#638CD33 binding agents
#639SELECTIVE ELIMINATION OF EROSIVE CELLS
#640Engineered antibody-interferon mutant fusion molecules
#641IMMUNE-CHECKPOINT INHIBITORS FOR USE IN THE TREATMENT OF BLOOD-BORNE CANCERS
#642Methods for inhibiting the binding of endosialin to ligands
#643T-cell redirecting bispecific antibodies for treatment of disease
#644Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof
#645Methods for identifying and isolating cells expressing a polypeptide
#646Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
#647Humanized anti-CD22 antibody
#648CYS80 conjugated immunoglobulins
#649Anti-CLL-1 antibodies and methods of use
#650Soluble MIC neutralizing monoclonal antibody for treating cancer
#651Human CD3 binding antibody
#652SELF-BUFFERING PROTEIN FORMULATIONS
#653Methods of Treating and Preventing Minor Histocompatibility Antigen-Mismatched Grafts
#654ANTIBODY VACCINE CONJUGATES AND USES THEREFOR
#655Monoclonal antibodies against the DEC-205 receptor of chicken dendritic cells
#656Multimeric Complexes with Improved in Vivo Stability, Pharmacokinetics and Efficacy
#657Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#658Deimmunized Serum-Binding Domains and Their Use in Extending Serum Half-Life
#659Tumor vascular marker-targeted vaccines
#660Recombinant production of mixtures of antibodies
#661Anti-human BDCA-2 antibody
#662ANTI-INFLAMMATORY POLYPEPTIDES
#663MODULATION OF NKG2D
#664Peptidomimetic compounds and antibody-drug conjugates thereof
#665COMBINATION THERAPY FOR TREATING ADULT PATIENTS WITH RELAPSED/REFRACTORY CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
#666Antibody-SN-38 immunoconjugates with a CL2A linker
#667Immunoconjugates with an intracellularly-cleavable linkage
#668Depletion of plasmacytoid dendritic cells
#669Peptidomimetic compounds and antibody-drug conjugates thereof
#670Peptidomimetic compounds and antibody-drug conjugates thereof
#671Antibody-drug conjugate
#672Fibrosis Inhibiting Compounds and Methods of Use Thereof in the Prevention or Treatment of Fibrosing Diseases
#673Bispecific single chain antibodies with specificity for high molecular weight target antigens
#674Conjugated antibodies against LY75 for the treatment of cancer
#675Antibody-SN-38 immunoconjugates with a CL2A linker
#676THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR INDUCING TROGOCYTOSIS
#677Antibody specific for CD22 and methods of use thereof
#678TARGETING THE M2-TUMOR ASSOCIATED MACROPHAGE FOR CANCER THERAPY
#679ANTI-GALECTIN-1 (GAL1) MONOCLONAL ANTIBODIES AND FRAGMENTS THEREOF FOR NEUTRALIZING GAL1
#680Compositions Associated with and Methods of Managing Neutrophil Movement
#681Methods Of Identifying Anti-Inflammatory Compounds
#682T-cell redirecting bispecific antibodies for treatment of disease
#683T-Cell Redirecting Bispecific Antibodies for Treatment of Disease
#684Anti-galectin-1 monoclonal antibodies and fragments thereof
#685Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
#686Insertable variable fragments of antibodies and modified A1-A2 domains of NKG2D ligands
#687Glycoengineered antibody drug conjugates
#688Targeting agent antibody conjugates and uses thereof
#689Treatment of cancer using a CD33 chimeric antigen receptor
#690Anti-CLL-1 antibodies and immunoconjugates
#691PYRROLOBENZODIAZEPINES AND ANTIBODY DISULFIDE CONJUGATES THEREOF
#692Site-specific glycoengineering of targeting moieties
#693Methods and compositions of treating autoimmune diseases
#694Treatment of cancer using a CLL-1 chimeric antigen receptor
#695exotoxin A with less immunogenic B cell epitopes
#696Methods and agents for treating Alzheimer's disease
#697LLT-1 antibodies with new functional properties
#698Antibodies Against Human NKG2D and Uses Thereof
#699Method of imaging a cardiovascular disease with an anti-macrophage mannose receptor immunoglobulin single variable domain
#700MOLECULAR CONJUGATES COMPRISING HUMAN MONOCLONAL ANTIBODIES TO DENDRITIC CELLS
#701ANTI-CD22 ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THEREOF
#702Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
#703Antibodies specific for CLL-1
#704Use of NKG2D Inhibitors for Treating Cardiovascular and Metabolic Diseases, Such as Type 2 Diabetes
#705Anti-inflammatory polypeptides
#706Methods and Compositions for Generating Bioactive Assemblies of Increased Complexity and Uses
#707MDL-1 ligand
#708HLA-E BINDING
#709Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases
#710Antibody targeting osteoclast-related protein siglec-15
#711Humanized anti-CD22 antibody
#712TEM-1 diagnostic antibodies
#713METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES OR CONDITIONS
#714Methods of producing immunoconjugates
#715Targeting and in vivo imaging of tumor-associated macrophages
#716Methods for identifying and isolating cells expressing a polypeptide
#717Antibody-SN-38 immunoconjugates with a CL2A linker
#718Anti-blood dendritic cell antigen 2 antibodies and uses thereof
#719ASGPR antibodies and uses thereof
#720Antibody-drug conjugate
#721CD33 binding agents
#722Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
#723MODULATION OF PODOPLANIN MEDIATED PLATELET ACTIVATION
#724Humanized anti-CD22 antibody
#725Compositions and Methods for Delivery of Antigens to Plasmacytoid Dendritic Cells
#726Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#727Deimmunized serum-binding domains and their use in extending serum half-life
#7281-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
#729Antibody specific for CLEC14A and uses thereof
#730Methods of treating tumors with engineered antibody-interferon mutant fusion molecules
#731Nanoemulsions
#732NOVEL ANTI-SIGLEC-15 ANTIBODY
#733Monoclonal antibodies against NKG2A
#734Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
#735Modular nanodevices for smart adaptable vaccines
#736ANTI-HUMAN CD69 ANTIBODY, AND USE THEREOF FOR MEDICAL PURPOSES
#737Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
#738Anti-CD22 antibodies
#739Methods for inhibiting the binding of endosialin to ligands
#740Hyperglycosylated binding polypeptides
#741Anti-NKG2A antibodies and uses thereof
#742GENETICALLY MODIFIED NON-HUMAN MAMMALS AND CELLS
#743ENHANCEMENT OF PATHOGEN-SPECIFIC MEMORY TH17 CELL RESPONSES
#744Methods and compositions for inhibiting CD32B expressing cells
#745Methods and compositions for inhibiting CD32b expressing cells
#746COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD22 ANTIBODY-DRUG CONJUGATE
#747Lectin-like oxidized LDL receptor 1 antibodies and methods of use
#748Lectin-like oxidized LDL receptor 1 antibodies and methods of use
#749Non-sialylated anti-inflammatory polypeptides
#750Methods and compositions involving NKG2D inhibitors and cancer
#751Methods for the treatment or prevention of systemic sclerosis
#752Humanized anti-human NKG2A monoclonal antibody
#753Immune modulation via C-type lectin
#754MITIGATION OF DISEASE BY INHIBITION OF GALECTIN-12
#755THERAPEUTIC APPLICATIONS OF ACTIVATION OF HUMAN ANTIGEN-PRESENTING CELLS THROUGH DECTIN-1
#756Site-specific antibody-drug conjugation through glycoengineering
#757Anti-DDR1 antibody having anti-tumor activity
#758MODULATORS OF 4-1BB AND IMMUNE RESPONSES
#759METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING CLEC-2
#760THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR INDUCING TROGOCYTOSIS
#761Compositions and methods to immunize against hepatitis C virus
#762DDR1-binding agents and methods of use thereof
#763Stable compositions of high-concentration allotype-selected antibodies for small-volume administration
#764Ultrafiltration concentration of allotype selected antibodies for small-volume administration
#765Antibody specific for CD22 and methods of use thereof
#766Selective elimination of erosive cells
#767IMMUNOTHERAPY OF B CELL MALIGNANCIES AND AUTOIMMUNE DISEASES USING UNCONJUGATED ANTIBODIES AND CONJUGATED ANTIBODIES AND ANTIBODY COMBINATIONS AND FUSION PROTEINS
#768Lipoparticles comprising proteins, methods of making, and using the same
#769Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
#770Bispecific IgG antibodies as T cell engagers
#771Modulation of NKG2D for prolonging survival of a hematopoietic graft
#772Method for preparing Fc containing polypeptides having improved properties
#773T-cell redirecting bispecific antibodies for treatment of disease
#774Vaccines directed to langerhans cells
#775Methods for identifying and isolating cells expressing a polypeptide
#776Methods for identifying and isolating cells expressing a polypeptide
#777Methods and compositions for inhibiting CD32B expressing cells
#778Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin
#779Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
#780Antibodies specific for CLL-1
#781Method of treating type 1 diabetes by administering NKp46 polypeptide
#782Self-buffering antibody formulations
#783Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
#784TEM-1 diagnostic antibodies
#785Inhibition of CD69 for treatment of inflammatory conditions
#786Removal of high molecular weight aggregates using hydroxyapatite chromatography
#787NON-FUCOSYLATED ANTIBODIES
#788LLT-1 antibodies with new functional properties
#789Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
#790Antibodies with enhanced or suppressed effector function
#791DENDRITIC CELL IMMUNORECEPTOR AGONIST
#792Controlling allergy and asthma by activating human DCs via Dectin-1 or toll-like receptor 2 (TLR2)
#793Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#794Stable antibody containing compositions
#795Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
#796METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES OR CONDITIONS
#797Immunoconjugates with an intracellularly-cleavable linkage
#798Methods and compositions for inhibiting CD32B expressing cells
#799Ultrafiltration concentration of allotype selected antibodies for small-volume administration
#800Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
#801BIOLOGICAL PRODUCTS
#802COMPOSITIONS AND METHODS TO IMMUNIZE AGAINST HEPATITIS C VIRUS
#803Targeting and in vivo imaging of tumor-associated macrophages
#804Anti-TEM1 antibodies and uses thereof
#805Dendritic Cell Marker BDCA-2 Protein Sequence
#806Ligating BDCA-2 protein with BDCA-2 specific antibody for detecting or modulating dendritic cells
#807Dendritic Cell Populations that are Enriched for Cells that Bear the BDCA-1 Antigen
#808CLEC14A inhibitors
#809Binding molecules for the treatment of myeloid cell malignancies
#810Dual Variable Domain Immunoglobulins and Uses Thereof
#811COMPOSITIONS AND METHODS OF MONOCLONAL AND POLYCLONAL ANTIBODIES SPECIFIC FOR T CELL SUBPOPULATIONS
#812GalNAc-SPECIFIC BINDING MOLECULES AND USES THEREOF
#813Antibody targeting osteoclast-related protein Siglec-15
#814Dendritic Cells (DCs) Targeting for Tuberculosis (TB) Vaccine
#815Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
#816Anti-NKG2A antibodies and uses thereof
#817Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells
#818Antibody targeting osteoclast-related protein siglec-15
#819Compositions and methods for identifying response targets and treating flavivirus infection responses
#820TH1/TH2 polarizing vaccines
#821MDL-1 USES
#822Methods and compositions for inhibiting CD32B expressing cells
#823Methods and compositions for inhibiting CD32B expressing cells
#824Monoclonal antibodies to dendritic cells
#825USE OF NKG2D INHIBITORS FOR TREATING CARDIOVASCULAR AND METABOLIC DISEASES, SUCH AS TYPE 2 DIABETES
#826Methods and compositions for inhibiting CD32b expressing cells
#827Enhancement of Pathogen-Specific Memory Th17 Cell Responses
#828Inhibition of CD69 for treatment of inflammatory conditions
#829Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases
#830METHOD OF TREATING AUTOIMMUNE DISEASE BY INDUCING ANTIGEN PRESENTATION BY TOLERANCE INDUCING ANTIGEN PRESENTING CELLS
#831CD33 binding agents
#832Method of treating diabetes by administering an anti-NKp46 antibody
#833Antibodies and kits for immunodetection of epitope tags
#834MODULATION OF NKG2D
#835Method for inhibiting dendritic cell immunoreceptor (DCIR)-mediated human immunodeficiency virus infection comprising administering anti-DCIR antibodies
#836Methods of using molecular conjugates comprising monoclonal antibodies to dendritic cells
#837Compounds and Methods for Modulating an Immune Response
#838Tumor vascular marker-targeted vaccines
#839Single chain multivalent binding proteins with effector function
#840Methods for the treatment or prevention of systemic sclerosis
#841CROSS-SPECIES-SPECIFIC PSCAxCD3, CD19xCD3, C-METxCD3, ENDOSIALINxCD3, EPCAMxCD3, IGF-1RxCD3 OR FAPALPHAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
#842Self-Buffering Protein Formulations
#843Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
#844PREVENTION OF TYPE 1 DIABETES BY TREG VACCINATION WITH AN INSULIN MIMETOPE
#845Method for production of antibody using ostrich
#846Stabilized polypeptide compositions
#847Method of producing anti-CD166 antibody in ostrich
#848Methods for identifying and isolating cells expressing a polypeptide
#849METHODS FOR MONOCLONAL ANTIBODY PRODUCTION
#850DDR1-binding agents and methods of use thereof
#851DENDRITIC CELL IMMUNORECEPTORS (DCIR)-MEDIATED CROSSPRIMING OF HUMAN CD8+ T CELLS
#852Bispecific single chain antibodies with specificity for high molecular weight target antigens
#853Selective targeting of intratumoral cells
#854LIGANDS THAT HAVE BINDING SPECIFICITY FOR DC-SIGN
#855Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells
#856Hybrid antibodies
#857Monoclonal Antibodies Against NKG2A
#858Composition for targeting dendritic cells
#859Targeting construct comprising anti-polymer antibody and contrast/therapeutic agents binding to the same
#860Methods and compositions for generating bioactive assemblies of increased complexity and uses
#861Methods, systems and reagents for improved immunodetection
#862Recombinant production of mixtures of antibodies
#863Biological products
#864Methods of treating cancer
#865ANTIBODIES WITH MANNOSE BINDING LECTIN EFFECTOR FUNCTION FOR INHIBITING PATHOLOGIC INFLAMMATORY CONDITIONS
#866Multi-Specific Binding Proteins Targeting B Cell Disorders
#867Fully human anti-human NKG2D monoclonal antibodies
#868Methods of Detecting Cells with a Disrupted Cell Membrane, Cells Infected with A Pathogen, Dying Cells or Dead Cells
#869ANTIBODY PURIFICATION PROCESS
#870VACCINES DIRECTED TO LANGERHANS CELLS
#871Methods Of Treating Viral Hepatitis
#872Methods of identifying anti-inflammatory compounds
#873Humanized anti-human NKG2A monoclonal antibody
#874Dual Variable Domain Immunoglobulins and Uses Thereof
#875USES OF ANTIBODIES TO MAMMALIAN DC LANGERHANS CELL ANTIGEN
#876SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION
#877Methods for inhibiting the binding of endosialin to ligands
#878Hybrid antibodies
#879Antibodies to CLL-1
#880Antibodies against human NKG2D and uses thereof
#881ENDOSIALIN BINDING MOLECULES
#882Anti-NKG2A antibodies and uses thereof
#883Immune modulation via C-type lectin
#884MDL-1 USES
#885Antibody targeting osteoclast-related protein Siglec-15
#886Binding molecules for the treatment of myeloid cell malignancies
#887Modulation of NKG2D
#888Methods and Compositions For Treating Autoimmune Diseases or Conditions
#889Anti-MDL-1 antibodies
#890CD161 ligand, pilar, for modulating activation and proliferation of T cells
#891Light targeting molecules and uses thereof
#892Fusion Proteins Comprising Two or More IgG Binding Domains of Streptococcal Protein G
#893Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
#894Hybrid antibodies
#895Identification of therapeutic agents for HIV infection
#896Antibodies against human NKG2D and uses thereof
#897Methods and reagents for the analysis and purification of polysaccharides
#898GAINAC SPECIFIC BINDING MOLECULES AND USES THEREOF
#899Biological products
#900Antibodies with immune effector activity and that internalize in endosialin-positive cells